Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center
SAMUEL BAKHOUM, M.D., PH.D.
Dr. Bakhoum is a co-founder of Volastra Therapeutics and serves on its board of directors. He is both a practicing radiation oncologist who specializes in the treatment of breast cancer and a leading investigator into the role of chromosomal instability in tumor evasion. The Bakhoum Lab at Memorial Sloan Kettering Cancer Center (MSKCC) has pioneered the development of cell- and animal-based models to explore the role of CIN in therapeutic resistance and metastasis. He obtained his M.D., Ph.D. at Dartmouth Medical School, where his graduate research focused on understanding the basic mechanisms of chromosome segregation during cell division. He subsequently completed an internship at Mount Auburn Hospital of Harvard Medical School and his residency training in radiation oncology at MSKCC. While a resident, he conducted research under the mentorship of Dr. Lewis Cantley at Weill Cornell Medicine, focusing on the role of chromosomal instability in tumor metastasis and the generation of a cytosolic DNA response.